

Table S1. Patient characteristics based on MET status (first/second generation cohort, N = 124)

	MET – (N = 109)	MET + (N = 15)	
	N (%)	N (%)	<i>P</i> value
Median age, years (range)	60 (28–84)	62 (43–73)	0.549
Sex			
Male	41 (37.6%)	5 (33.3%)	
Female	68 (62.4%)	10 (66.7%)	0.748
Smoking status			
Current smoker	5 (4.6%)	0 (0.0%)	
Ex-smoker	29 (26.6%)	6 (40.0%)	
Never smoker	75 (68.8%)	9 (60.0%)	
Median pack-year of smoking (interquartile range)	0.0 (0.0 – 15.0)	0.0 (0.0 – 18.0)	0.663
Previous TKI line			
First line	93 (85.3%)	11 (73.2%)	
Second line	15 (13.8%)	3 (20.0%)	
Third line	1 (0.9%)	1 (6.7%)	0.194
Founder <i>EGFR</i> mutation			
Exon 19 deletion	60 (55.0%)	9 (60.0%)	
L858R	40 (36.7%)	5 (33.3%)	
Other mutations**	9 (8.3%)	1 (6.7%)	0.932
Liver metastasis			
No metastases	93 (85.3%)	7 (46.7%)	
Baseline metastases without progression	0 (0.0%)	3 (20.0%)	
Baseline metastases with progression	3 (2.8%)	4 (26.7%)	
Progression with new lesion	13 (11.9%)	1 (6.7%)	0.071*
Brain metastasis			
No metastases	29 (26.6%)	8 (53.3%)	
Baseline metastases without progression	5 (4.6%)	4 (26.7%)	
Baseline metastases with progression	47 (43.1%)	2 (13.3%)	
Progression with new lesion	24 (22.0%)	1 (6.7%)	< 0.001*
Not evaluated	4 (3.7%)	0 (0.0%)	

MET, mesenchymal epithelial transition factor; TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor; SD, standard deviation.

*Between progression versus no progression

**Other mutations include exon 20 insertion (p.A767_V769dup) (N = 1), G719X (N = 2), L861Q (N = 4), and S768I (N = 2) in MET (-) group and G179S/L861Q (N = 1) in MET (+) group.

**Table S2. Patient characteristics based on MET status
(third generation cohort, N = 62)**

	MET – (N = 47)	MET + (N = 15)	
	N (%)	N (%)	P value
Median age, years (range)	61 (40–81)	55 (28–76)	0.067
Sex			
Male	16 (34.0%)	8 (53.3%)	0.182
Female	31 (66.0%)	7 (46.7%)	
Smoking			
Current smoker	3 (6.4%)	1 (6.7%)	0.205
Ex-smoker	8 (17.0%)	9 (60.0%)	
Never smoker	36 (76.6%)	5 (33.3%)	
Median pack-year of smoking (interquartile range)	0.0 (0.0 – 0.0)	4.0 (0.0 – 33.0)	0.205
Previous TKI line			
First line	0 (0.0%)	0 (0.0%)	0.068
Second line	43 (91.5%)	11 (73.3%)	
Third line	4 (8.5%)	4 (26.7%)	
Founder <i>EGFR</i> mutation			
Exon 19 deletion	28 (59.6%)	10 (66.0%)	0.623
L858R	19 (40.4%)	5 (33.3%)	
Other mutations	0 (0.0%)	0 (0.0%)	
Liver metastasis			
No metastases	32 (68.1%)	11 (73.3%)	0.817*
Baseline metastases without progression	1 (2.1%)	0 (0.0%)	
Baseline metastases with progression	1 (2.1%)	3 (20%)	
Progression with new lesion	13 (27.7%)	1 (6.7%)	
Brain metastasis			
No metastases	15 (31.9%)	8 (53.3%)	0.029*
Baseline metastases without progression	2 (4.3%)	3 (20.0%)	
Baseline metastases with progression	12 (25.5%)	3 (20.0%)	
Progression with new lesion	13 (27.7%)	1 (6.7%)	
Not evaluated	5 (10.6%)	0 (0.0%)	

MET, mesenchymal epithelial transition factor; TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor; SD, standard deviation.

*Between progression versus no progression